Thrivent Financial for Lutherans trimmed its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 5.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 605,120 shares of the biotechnology company's stock after selling 33,482 shares during the quarter. Thrivent Financial for Lutherans owned 1.08% of Repligen worth $87,101,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of RGEN. Atria Investments Inc increased its holdings in shares of Repligen by 67.9% in the 3rd quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company's stock valued at $477,000 after purchasing an additional 1,295 shares during the period. CIBC Asset Management Inc acquired a new position in Repligen in the third quarter worth approximately $242,000. Natixis Advisors LLC increased its holdings in Repligen by 53.6% in the third quarter. Natixis Advisors LLC now owns 33,625 shares of the biotechnology company's stock worth $5,004,000 after buying an additional 11,731 shares during the last quarter. Quest Partners LLC acquired a new position in Repligen in the third quarter worth approximately $166,000. Finally, LMR Partners LLP acquired a new position in Repligen in the third quarter worth approximately $3,597,000. 97.64% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on RGEN shares. JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Finally, Canaccord Genuity Group increased their price objective on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $178.64.
View Our Latest Analysis on RGEN
Repligen Price Performance
Shares of RGEN traded up $0.68 during trading hours on Friday, hitting $140.02. The stock had a trading volume of 623,142 shares, compared to its average volume of 651,868. The company's fifty day moving average is $156.18 and its two-hundred day moving average is $148.37. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $198.00. The stock has a market capitalization of $7.86 billion, a price-to-earnings ratio of -274.55, a P/E/G ratio of 4.54 and a beta of 0.95.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.
Insider Transactions at Repligen
In other news, Director Margaret Pax acquired 250 shares of the company's stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.20% of the company's stock.
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
